HuGE Literature Finder
Records
1
-
24
| Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers. iScience 2023 2 26 (3): 106082. Tyc Katarzyna M, Kazi Aslamuzzaman, Ranjan Alok, Wang Rui, Sebti Said |
| The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. Journal of the National Cancer Institute 2022 May . Umemoto Kumiko, Yamamoto Hiroyuki, Oikawa Ritsuko, Takeda Hiroyuki, Doi Ayako, Horie Yoshiki, Arai Hiroyuki, Ogura Takashi, Mizukami Takuro, Izawa Naoki, Moore Jay A, Sokol Ethan S, Sunakawa |
| PROshot: Locoregional Therapy for Metastatic Breast Cancer, Abiraterone in Very High-Risk Prostate Cancer, Neoadjuvant Chemoradiation for Resectable Pancreatic Cancer, Radiation for Oligometastatic EGFR-mutated Lung Cancer, and PORT for N2 Lung Cancer. Practical radiation oncology 2022 5 12 (3): 179-184. Dulaney Caleb, Dover Lau |
| A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study). Annals of surgical oncology 2021 Mar . Matsudera Shotaro, Kano Yoshihito, Aoyagi Yasuko, Tohyama Kohki, Takahashi Kenta, Kumaki Yuichi, Mitsumura Takahiro, Kimura Koichiro, Onishi Iichiro, Takemoto Akira, Ban Daisuke, Ono Hiroaki, Kudo Atsushi, Oshima Noriko, Ogino Kei, Watanabe Shun, Tani Yukiko, Yamaguchi Takeshi, Nakajima Masanobu, Morita Shinji, Yamaguchi Satoru, Takagi Masatoshi, Ishikawa Toshiaki, Nakagawa Tsuyoshi, Okamoto Kentaro, Uetake Hiroyuki, Tanabe Minoru, Miyake Satoshi, Tsuchioka Takashi, Kojima Kazuyuki, Ikeda Sadakat |
| Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). International journal of cancer 2021 Feb 148 (3): 682-691. Assenat Eric, Mineur Laurent, Mollevi Caroline, Lopez-Crapez Evelyne, Lombard-Bohas Catherine, Samalin Emmanuelle, Portales Fabienne, Walter Thomas, de Forges Hélène, Dupuy Marie, Boissière-Michot Florence, Ho-Pun-Cheung Alexandre, Ychou Marc, Mazard Thiba |
| Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer. World journal of gastroenterology 2021 10 27 (36): 6093-6109. Rah Bilal, Banday Manzoor Ahmad, Bhat Gh Rasool, Shah Omar J, Jeelani Humira, Kawoosa Fizalah, Yousuf Tahira, Afroze D |
| Influence of Sex in the Molecular Characteristics and Outcomes of Malignant Tumors. Frontiers in oncology 2021 11 752918. Araujo Jhajaira M, Rosas Gina, Belmar-López Carolina, Raez Luis E, Rolfo Christian D, Schwarz Luis J, Infante-Huaytalla Ulises, Paez Kevin J, García Luis R, Alvarado Hober, Ramos Fany P, Delgado-Espinoza Sheyla S, Cardenas-Farfan Jhon B, Cornejo Melanie, Zanabria Daniel, Colonio-Cossio Christian, Rojas-Jefferson Mario, Pinto Joseph |
| Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study. European journal of clinical pharmacology 2020 May . Han Ji Min, Han Hye Won, Yee Jeong, Kim Min Kyoung, Moon Jin Young, Cho Soyeon, Jung Dasom, Cho Yoon Sook, Seo Inyoung, Kim Jae Youn, Gwak Hye S |
| Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG). ESMO open 2019 4 (5): e000525. Zarkavelis George, Kotoula Vassiliki, Kolliou Georgia-Angeliki, Papadopoulou Kyriaki, Tikas Ioannis, Karavasilis Vasilios, Samantas Epaminontas, Dervenis Christos, Efstratiou Ioannis, Nicolaou Irene, Apessou Dimitra, Kafiri Georgia, Koletsa Triantafyllia, Bompolaki Iliada, Rallis Grigorios, Batistatou Anna, Glantzounis George, Pectasides Dimitrios, Fountzilas George, Pentheroudakis Geor |
| Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study. BMC cancer 2018 10 18 (1): 988. Kim Min Kyoung, Yee Jeong, Cho Yoon Sook, Jang Hong Won, Han Ji Min, Gwak Hye S |
| Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. International journal of cancer 2017 Feb . Cheng He, Liu Chen, Jiang Jiahao, Luo Guopei, Lu Yu, Jin Kaizhou, Guo Meng, Zhang Zhenzhen, Xu Jin, Liu Liang, Ni Quanxing, Yu Xianj |
| Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach. Cancer genetics 2015 Sep 208 (9): 441-7. Hagemann Ian S, O'Neill Patrick K, Erill Ivan, Pfeifer John |
| Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget 2015 Jul 6 (20): 18162-73. Wang Jack P, Wu Chen-Yi, Yeh Yi-Cheng, Shyr Yi-Ming, Wu Ying-Ying, Kuo Chen-Yu, Hung Yi-Ping, Chen Ming-Huang, Lee Wei-Ping, Luo Jiing-Chyuan, Chao Yee, Li Chung-P |
| Association of single nucleotide polymorphisms of ß2-adrenergic receptor gene with clinicopathological features of pancreatic carcinoma. Acta histochemica 2013 Apr 115 (3): 198-203. Wenjuan Yu, Yujun Li, Ceng |
| KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. Journal of gastroenterology 2013 Apr 48 (4): 544-8. Boeck Stefan, Jung Andreas, Laubender Rüdiger P, Neumann Jens, Egg Rosalind, Goritschan Clara, Ormanns Steffen, Haas Michael, Modest Dominik P, Kirchner Thomas, Heinemann Volk |
| Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. Journal of gastrointestinal oncology 2013 Mar 4 (1): 20-9. Weiss Guy A, Rossi Michael R, Khushalani Nikhil I, Lo Ken, Gibbs John F, Bharthuar Anubha, Cowell John K, Iyer Renu |
| EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. British journal of cancer 2012 Nov . Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Klein S, Kojouharoff G, Barner M, Geissler M, Greten TF, Mansmann U, Kirchner T, Heinemann V |
| A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational new drugs 2012 Jun 30 (3): 1164-74. Oh Do-Youn, Lee Keun Wook, Lee Kyung-Hee, Sohn Chang-Hak, Park Young Suk, Zang Dae Young, Ryoo Hun-Mo, Song Hong-Suk, Kim Jin-Soo, Kang Hye-Jin, Kim Bong-Seog, Bang Yung-J |
| Clinical relevance of epidermal growth factor receptor (EGFR) alterations in human pancreatic tumors. Oncology reports 2011 Aug 26 (2): 315-20. Lozano-Leon Antonio, Perez-Quintela Begona Vieites, Iglesias-García Julio, Urisarri-Ruiz Adela, Lariño-Noia Jose, Abdulkader Ihab, Varo Evaristo, Forteza Jeronimo, Domínguez-Muñoz J Enriq |
| Clinical significance of miR-146a in gastric cancer cases. Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Jul 17 (13): 4277-84. Kogo Ryunosuke, Mimori Koshi, Tanaka Fumiaki, Komune Shizuo, Mori Masa |
| KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology 2011 81 (1): 3-8. Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger M M, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A, Endlicher |
| Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma. American journal of surgery 2010 Sep 200 (3): 398-405. Frolov Andrey, Liles J Spencer, Kossenkov Andrew V, Tzeng Ching-Wei D, Jhala Nirag, Kulesza Peter, Varadarajulu Shyam, Eloubeidi Mohamad, Heslin Martin J, Arnoletti J Pab |
| Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Annals of surgical oncology 2007 Jul 14 (7): 2150-8. Tzeng Ching-Wei D, Frolov Andrey, Frolova Natalya, Jhala Nirag C, Howard J Harrison, Vickers Selwyn M, Buchsbaum Donald J, Heslin Martin J, Arnoletti J Pab |
| Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007 Apr 109 (8): 1561-9. Lee Jeeyun, Jang Kee-Taek, Ki Chang-Seok, Lim Taekyu, Park Young Suk, Lim Ho Yeong, Choi Dong-Wook, Kang Won Ki, Park Keunchil, Park Joon |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 16, 2023
- Content source: